Workflow
OraSure Technologies(OSUR)
icon
Search documents
OraSure to Present at the J.P Morgan Healthcare Conference
Globenewswire· 2025-01-07 21:05
Company Overview - OraSure Technologies, Inc. is a leader in point-of-need and home diagnostic tests and sample management solutions [1] - The company aims to transform health through actionable insights and improve access, quality, and value of healthcare with innovative testing solutions [3] - OraSure's product portfolio includes rapid diagnostic tests and sample collection devices, sold globally to various healthcare entities [3] Upcoming Event - OraSure's management team will participate in the 43rd Annual J.P. Morgan Healthcare Conference [1] - The presentation is scheduled for January 16, 2025, at 9:00 a.m. PT [1] - A live webcast and replay of the presentation will be available on OraSure's investor relations website [2]
Are Investors Undervaluing OraSure Technologies (OSUR) Right Now?
ZACKS· 2025-01-07 16:06
Core Viewpoint - The article emphasizes the importance of value investing and highlights OraSure Technologies (OSUR) as a strong value stock based on various financial metrics [2][3][6] Company Analysis - OraSure Technologies (OSUR) currently holds a Zacks Rank of 2 (Buy) and has a Value grade of A, indicating it is considered a strong value stock [3] - The company's price-to-sales (P/S) ratio is 1.24, which is lower than the industry average of 1.72, suggesting that OSUR may be undervalued [4] - OSUR's price-to-cash flow (P/CF) ratio stands at 11.81, significantly lower than the industry's average of 37.04, indicating a favorable cash outlook for the company [5] - Over the past 52 weeks, OSUR's P/CF has fluctuated between 6.11 and 14.08, with a median of 8.27, further supporting the notion of its current undervaluation [5][6] Industry Insights - Value investing remains a preferred strategy for identifying strong stocks across various market conditions, relying on traditional valuation metrics [2] - The P/S ratio is favored by some investors as it is less susceptible to manipulation compared to earnings figures, making it a potentially more reliable performance indicator [4]
CORRECTION - OraQuick® HIV Self-Test Now Approved for Use in Adolescents
Newsfilter· 2025-01-07 13:50
Core Insights - OraSure Technologies, Inc. has received FDA approval for a labeling change to the OraQuick® HIV Self-Test, expanding its use to adolescents aged 14 and older, previously limited to those 17 and older [1] - The change aims to increase access to HIV testing for young people, addressing a significant gap as 19% of new HIV diagnoses in the U.S. are among individuals aged 13 to 24, with only 6% of high school students having ever been tested [2][3] Company Overview - OraSure Technologies is a leader in point-of-need and home diagnostic tests, focusing on improving access to healthcare through innovative testing solutions [1][4] - The company has been committed to providing consumers with critical information and connections to care since the launch of the OraQuick® HIV Self-Test in 2012, which includes educational materials and care linkage information [3][4] Industry Context - Increasing access to HIV testing options is crucial for ending the HIV epidemic, particularly for adolescents who test positive, emphasizing the need for early connection to care [3] - The approval of the OraQuick® HIV Self-Test for younger populations is a strategic move to combat the stigma surrounding HIV testing and improve awareness among adolescents [3]
OraQuick® HIV Self-Test Now Approved for Use in Adolescents
Globenewswire· 2025-01-07 12:05
Company Overview - OraSure Technologies, Inc. is focused on transforming health through actionable insights and improving access, quality, and value of healthcare with innovative testing solutions [4] - The company, along with its subsidiaries, is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection devices [4] Product Update - The OraQuick HIV Self-Test has expanded its approved age range to include individuals aged 14 and older, previously limited to those 17 and older [1] - This change aims to increase access to HIV testing for adolescents, addressing a significant gap in testing among young people [1][3] Market Context - According to the CDC, 19% of new HIV diagnoses in the U.S. are among individuals aged 13 to 24, with only 6% of high school students having ever been tested for HIV [2] - Nearly half of young people with HIV are unaware of their status, highlighting the need for increased testing options [2] Company Commitment - OraSure is dedicated to promoting HIV testing and reducing the stigma associated with infection, providing educational materials and care linkage information with its products [3] - The OraQuick HIV Self-Test has been available to consumers in the U.S. since 2012, reflecting the company's long-term commitment to improving access to critical health information [3]
OSUR Stock Rises Following the Acquisition of Sherlock Biosciences
ZACKS· 2024-12-26 17:11
OraSure Technologies, Inc. (OSUR) recently announced the acquisition of Sherlock Biosciences, Inc., a global health company bringing next-generation diagnostics to consumers and healthcare providers.This acquisition enhances OraSure’s innovation pipeline by incorporating Sherlock Biosciences’ molecular diagnostics platform. This platform delivers rapid results with high sensitivity and specificity in a disposable format ideal for over-the-counter use.Likely Trend of OSUR Stock Following the NewsFollowing th ...
OraSure Technologies Acquires Sherlock Biosciences
Newsfilter· 2024-12-19 21:02
BETHLEHEM, Pa., Dec. 19, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. ("OTI") (NASDAQ:OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the acquisition of Sherlock Biosciences, Inc., a global health company bringing next-generation diagnostics to consumers and healthcare providers. This acquisition expands OraSure's innovation pipeline with the addition of Sherlock's molecular diagnostics platform, which is able to provide rapid results with s ...
OraSure Technologies: Discounted Assets With An Attractive Free Call Option
Seeking Alpha· 2024-12-11 18:34
I worked for many years at an investment firm where I invested across public and private market opportunities. I underwrote fund managers, as well as individual securities. I left the firm to pursue an MBA from a Top-20 US B School. At school, I won the nation's premier stock pitching competition and was portfolio manager for the school's Consumer sector investments. During that time, I interned at a multi-family office and a hedge fund. I became adept at using Bloomberg and Factset for research. On top of ...
OraSure Receives Federal Funding for Development of Marburg Virus Rapid Antigen Test
GlobeNewswire News Room· 2024-12-02 12:05
BETHLEHEM, Pa., Dec. 02, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-care and home diagnostic tests and sample management solutions, today announced that it received an award through the Rapid Response Partnership Vehicle (RRPV) for the development of a Marburg Virus Disease (MVD) rapid antigen test. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Resp ...
Is OraSure Technologies (OSUR) Stock Undervalued Right Now?
ZACKS· 2024-11-28 15:41
While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use tried-and-true metrics an ...
OraSure to Participate in Upcoming Investor Conference
GlobeNewswire News Room· 2024-11-18 21:05
BETHLEHEM, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that the company is scheduled to participate in the following investor conference: Stephens Annual Investment Conference on Wednesday, November 20, with a Q&A session scheduled for 1 p.m. ET A live webcast and replay of the Q&A session will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations. The webcast will be archived on OraSure’s ...